ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,180.74
      1.03%
      US Tech 100
      17,598.80
      1.03%
      Dow Jones
      38,852.27
      0.46%
      Brent Oil
      83.325
      -0.18%
      Bitcoin
      63,640.88
      0.75%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Achilles Therapeutics PLC (ACHL)

      7. Achilles Therapeutics PLC (ACHL) News

      ACHL

      Achilles Therapeutics (ACHL)

      Achilles Therapeutics PLC
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ACHL
      DateTimeSourceHeadlineSymbolCompany
      04/04/20246:45AMGlobeNewswire Inc.Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
      04/04/20246:30AMGlobeNewswire Inc.Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningNASDAQ:ACHLAchilles Therapeutics PLC
      02/05/20247:00AMGlobeNewswire Inc.Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceNASDAQ:ACHLAchilles Therapeutics PLC
      02/01/20241:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
      12/18/20237:00AMGlobeNewswire Inc.Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity PredictionNASDAQ:ACHLAchilles Therapeutics PLC
      11/13/20234:36PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
      11/13/20234:30PMGlobeNewswire Inc.Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
      11/01/20235:26PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
      09/22/20234:42PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
      09/22/20234:30PMGlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
      09/20/20238:45AMInvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ACHLAchilles Therapeutics PLC
      08/17/20233:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
      08/04/20237:42AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
      08/04/20237:00AMGlobeNewswire Inc.Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
      06/29/20234:04PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
      06/29/20234:03PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
      06/12/20238:00AMGlobeNewswire Inc.Achilles Therapeutics to Present at Upcoming ConferencesNASDAQ:ACHLAchilles Therapeutics PLC
      05/10/20238:47AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
      05/10/20237:15AMGlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
      05/10/20237:00AMGlobeNewswire Inc.Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensNASDAQ:ACHLAchilles Therapeutics PLC
      04/25/20236:00PMGlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
      04/25/20237:00AMGlobeNewswire Inc.Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusNASDAQ:ACHLAchilles Therapeutics PLC
      04/17/20238:00AMGlobeNewswire Inc.Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:ACHLAchilles Therapeutics PLC
      02/14/20234:03PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
      02/14/20234:02PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
      02/13/20236:05AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
      12/30/20224:58PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ACHLAchilles Therapeutics PLC
      12/23/20225:16PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ACHLAchilles Therapeutics PLC
      12/15/20225:03PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ACHLAchilles Therapeutics PLC
      11/09/20227:38AMTipRanksChardan Capital Keeps Their Buy Rating on Achilles Therapeutics (ACHL)NASDAQ:ACHLAchilles Therapeutics PLC
       Showing the most relevant articles for your search:NASDAQ:ACHL